Roivant Sciences is a clinical-stage biopharma holding company with its entire near-term value concentrated in brepocitinib and a HanAll Biopharma partnership, currently burning cash at 13,202% of revenue while showing improving earnings beat trends and analyst consensus implying 30% upside from current levels.
Thesis pillars
- Pipeline Concentration Brepocitinib↓Deteriorating
- Cash Burn Quality Floor→Stable
- Improving Earnings Beat Streak↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed May 20, 2026
Roivant Sciences Ltd. (ROIV) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $37.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Elevated put/call ratio: 8.52; Below-average business quality.
Roivant Sciences is a clinical-stage biopharmaceutical company that develops medicines through subsidiary 'Vant' entities each focused on specific programs. The lead asset, brepocitinib (JAK1/TYK2 inhibitor), has an FDA PDUFA date in 3Q 2026 for dermatomyositis; IMVT-1402, an... Read more
Sell if holding. Engine safety override at $37.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Elevated put/call ratio: 8.52; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Score 4.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Roivant Sciences Ltd.
About Roivant Sciences Ltd.
Roivant Sciences' most advanced asset, brepocitinib, received FDA Priority Review with a PDUFA target action date in 3Q 2026 for dermatomyositis—the company's first potential commercial product. As of March 31, 2026, Roivant held $4.3 billion in cash, cash equivalents, and marketable securities, with no commercial-stage products and an accumulated deficit of approximately $501.8 million. The company operates through subsidiary Vants including Priovant (72% owned), Immunovant (56% owned, publicly traded), and Pulmovant (97% owned).
Roivant earns no product revenue, funding operations entirely from its balance sheet while advancing three core programs. Priovant develops brepocitinib under a license from Pfizer that carries tiered sub-teens royalties on net sales and a mid-tens-of-millions sales milestone if annual net sales exceed a mid-hundreds-of-millions threshold. Immunovant develops IMVT-1402 (imeroprubart) under a license from HanAll Biopharma Co., Ltd. with milestones up to $420 million and tiered mid-single-digit to mid-teens royalties; Phase 2/3 trials are ongoing in Graves' disease, myasthenia gravis, Sjögren's disease, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, and cutaneous lupus erythematosus. Pulmovant develops mosliciguat under a license from Bayer with milestones up to $280 million and tiered high-single-digit royalties. The company also holds an 83% stake in Genevant, which announced a $2.25 billion settlement with Moderna in patent-infringement litigation, with $950 million payable to Genevant and Arbutus in July 2026.
Show full overview
Brepocitinib's 3Q 2026 FDA decision on dermatomyositis represents the most immediate binary catalyst, but multiple readouts cluster in 2H 2026: NIU topline data from the Phase 3 CLARITY study, mosliciguat Phase 2 data from the PHocus trial in pulmonary hypertension associated with interstitial lung disease, and IMVT-1402 data in cutaneous lupus erythematosus. The HanAll Agreement governing IMVT-1402 rights at Immunovant introduces a separate dependency: the 10-K notes that Immunovant's April 2026 decision to discontinue batoclimab development could prompt a dispute with HanAll, potentially affecting the broader anti-FcRn program.
See also: Healthcare · Biotechnology
From Roivant Sciences Ltd.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Roivant Sciences Ltd.
Latest news
- NEWS Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56 — benzinga Oct 28, 2026 positive
- NEWS If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today — benzinga Oct 28, 2026
- NEWS Why Is Roivant Sciences Stock Surging Wednesday? — benzinga Oct 21, 2026 positive
- NEWS Roivant and Priovant Announce Positive Phase 3 Results for Brepocitinib in Non-Infectious Uveitis — fiscal.ai Oct 21, 2026 positive
- NEWS Roivant Sciences Schedules Second Quarter Fiscal 2026 Financial Results Announcement — fiscal.ai Oct 21, 2026 neutral
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebrepocitinib10-K Item 1: 'Priovant's filing for use of brepocitinib in DM has been accepted by the FDA with Priority Review with a PDUFA target action date in the third quarter of calendar year 2026'
- HIGHcounterpartyHanAll Biopharma10-K Item 1A: 'Immunovant holds the intellectual property rights to IMVT-1402 and batoclimab under a license agreement with HanAll Biopharma Co., Ltd.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -33.5% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $37.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Elevated put/call ratio: 8.52; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Prior stop was $34.51. Score 4.1/10, moderate confidence.
Analyst target: $42.55 (+14.7% upside). Prior stop was $34.51. Stop-loss: $34.51.
Concentration risk — Pipeline: brepocitinib; Concentration risk — Counterparty: HanAll Biopharma; Quality below floor (1.5 < 4.0).
Roivant Sciences Ltd. trades at a P/E of N/A (forward -21.6). TrendMatrix value score: 6.0/10. Verdict: Sell.
20 analysts cover ROIV with a consensus score of 4.3/5. Average price target: $49.
What does Roivant Sciences Ltd. do?Roivant Sciences is a clinical-stage biopharmaceutical company that develops medicines through subsidiary 'Vant'...
Roivant Sciences is a clinical-stage biopharmaceutical company that develops medicines through subsidiary 'Vant' entities each focused on specific programs. The lead asset, brepocitinib (JAK1/TYK2 inhibitor), has an FDA PDUFA date in 3Q 2026 for dermatomyositis; IMVT-1402, an anti-FcRn antibody developed at Immunovant (56% owned), is in multiple Phase 2/3 trials. As of March 31, 2026, the company held $4.3 billion in cash with no commercial products.